Phathom Pharma Upgraded by Barclays to Overweight $18 Target
Barclays lifts Phathom Pharmaceuticals to Overweight with an $18 target, citing a stronger 2026 revenue trajectory an...
Understand which index funds to hold in retirement 2024, with practical tips on allocation, rebalancing, and long-term performance.
24,968 articlesBarclays lifts Phathom Pharmaceuticals to Overweight with an $18 target, citing a stronger 2026 revenue trajectory an...
Ethereum failed to push above the $2.4K threshold, leaving the asset trapped in a tightening range as traders weigh d...
XRP flashed a fresh TD Sequential buy signal on the 4-hour chart, renewing bets on a sharp advance as traders eye key...
After an 11% drop, investors wonder if CoreWeave stock can rebound. This article weighs the bull and bear cases, what...
Three under-$10 energy names are drawing attention as one yields 8.8%, another is up 83% in a year, and market chatte...
Pfizer has reset its growth trajectory with big bets on Seagen and a future GLP-1 drug. This analysis breaks down wha...
Brown University economist Mark Blyth outlines how a new Fed chair could steer policy through inflation and growth he...
Bitcoin stabilizes around $77,000 as two altcoins post double-digit gains from these, signaling renewed momentum and ...
Fannie Mae updates its crypto mortgage framework with a 250% collateral requirement, reshaping how crypto assets can ...
Driven Brands generated $1.9 billion in revenue, signaling a powerful multi-brand approach in the auto aftermarket. B...
Salesforce is set to release Q1 results as investors look for evidence that its AI strategy can rekindle growth. A re...
AI stocks keep surprising investors with durable growth. Here’s a detailed, practical case for a single stock that ch...